Across pooled trial datasets and meta-analyses, achieving pCR is strongly associated with improved event-free and overall survival in TNBC and HER2-positive breast cancer; the association is weaker and less frequent for HR-positive/HER2-negative tumors, in which endocrine therapy dominates long-term risk reduction [3,4]. This evidence concerns the gene ERBB2 and breast carcinoma.